KYPROLIS® (carfilzomib) 60mg
| Product Overview | |
| Generic Name | KYPROLIS® (carfilzomib) 60mg |
| Brand Name(s) | KYPROLIS® |
| Form | vial, Lyophilized IV powder for solution |
| Strength | 60 mg |
| Therapeutic Class | Antineoplastic, proteasome inhibitor |
| ATC Code | L01XG02 |
| Manufacturing & Regulatory | |
| Manufacturer | Takeda, Amgen |
| Country | India |
| GMP Compliance | WHO/EMA |
| DMF/CEP | #202714 |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 5 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | EXW |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| CTD Summary | Upon Request |
Description
Indications and Usage – KYPROLIS (carfilzomib) is indicated for the treatment of relapsed or refractory multiple myeloma, typically in combination with other agents such as lenalidomide and dexamethasone, or dexamethasone alone.
